Hormone Therapy & Heart Risk: What WHI Still Teaches Us in 2026

 

Inspired by a 2026 editorial reviewing the WHI legacy and new secondary analysis data.

This article isn’t about rehashing old hormone therapy fears. It’s about refining the message. More than 20 years after the Women’s Health Initiative (WHI), we’re no longer asking: “Is hormone therapy good or bad?”

We’re asking: "For which woman, at what time, and in what form?"

Let’s unpack what we now understand.

 

 

🚨 Quick Reframe: WHI Didn’t “Ban” Hormone Therapy — It Personalized It

The WHI trials enrolled over 27,000 postmenopausal women — most in their early 60s and more than 10 years past menopause.

What they found:

  • Oral conjugated equine estrogen (CEE) + medroxyprogesterone acetate (MPA) increased coronary heart disease events.
  • Both CEE alone and CEE+MPA increased stroke and venous thromboembolism (VTE).
  • Risk was not uniform — age and time since menopause mattered significantly.

The key insight?

Cardiovascular risk with hormone therapy is strongly modified by timing and baseline risk.

This is the origin of what we now call the “timing hypothesis.”

 

 

🧠 What This New Analysis Asked

A new secondary WHI analysis explored:

If a woman is taking aspirin or a statin…
Can those medications offset the cardiovascular risks of oral estrogen?

The answer?

Not meaningfully.

Baseline statin or aspirin use did not reliably reduce the excess risk of coronary, stroke, or VTE events associated with oral CEE-based therapy.

Translation:

Statins and aspirin are not “rescue therapy” for a higher-risk hormone regimen.

They should be prescribed based on overall cardiovascular risk — not as compensation.

 

 

🔬 What We’ve Learned Since WHI

European and French data refined the story further.

Key findings:

  • Oral estrogen increases VTE and stroke risk more than transdermal estrogen.
  • Transdermal estradiol (especially low-dose) appears to have a more favorable thrombotic profile.
  • Progestogen type matters:
    • Norpregnane derivatives carry higher VTE risk.
    • Micronized progesterone appears safer in observational data.

This shifts the conversation from:

“Is hormone therapy safe?”

to: “Which formulation best aligns with this woman’s risk profile?”

 

 

⚠️ Clinical Takeaways for Midlife Women

Here’s what remains true:

Hormone therapy is not a cardiovascular prevention tool.

It is primarily for symptom management.

The most favorable cardiovascular profile appears in women who:

  • Are younger than 60
  • Are within 10 years of menopause onset
  • Have low baseline cardiovascular risk
  • Use low-dose transdermal estradiol
  • Use micronized progesterone when needed

Risk increases when therapy is initiated:

  • More than 10 years after menopause
  • In women with higher baseline cardiovascular risk
  • Using oral CEE ± MPA regimens

 

 

🌱 The Bigger Strategic Message

WHI did not “condemn” hormone therapy.

It taught us precision.

It moved us away from universal prescribing and toward individualized cardiovascular risk assessment.

Today’s practice is different:

  • Lower doses
  • Different estrogen formulations (17β-estradiol)
  • Transdermal options
  • More nuanced progestogen selection
  • Better cardiovascular risk stratification

We’re not practicing 2002 medicine anymore.

 

 

💡 What You Can Do This Month

Here’s how this applies to real life:

1️⃣ Know Your Cardiovascular Baseline
Before starting or continuing hormone therapy, review:

  • Lipid profile
  • Blood pressure
  • A1c or fasting glucose
  • Family history
  • BMI and waist circumference

Prevention is layered.

2️⃣ If You’re on Hormone Therapy — Review the Route
Ask:

  • Is my estrogen oral or transdermal?
  • What progestogen am I using?
  • Does this align with my cardiovascular risk?

Delivery and formulation matter.

3️⃣ Don’t Rely on “Add-Ons”
Statins and aspirin have roles — but not as protection against a higher-risk hormone regimen.

Each medication should stand on its own indication.

4️⃣ Focus on Global Risk Reduction
The strongest cardiovascular protection still comes from:

  • Strength training
  • Metabolic health optimization
  • Blood pressure control
  • Lipid management
  • Sleep
  • Smoking avoidance

Hormones are one piece — not the entire puzzle.

 

 

💛 Final Thought

The WHI didn’t end hormone therapy. It matured it.

We now understand that the safest approach isn’t blanket avoidance — it’s individualized timing, formulation, and risk assessment.

The goal is not just symptom relief. It’s protecting long-term health span while honoring quality of life.

And that requires strategy — not fear.

 

Citation:
Canonico M. Women, menopause, hormone therapy, and cardiovascular disease: what WHI still teaches us in 2025, and where are we now? Menopause. 2026;33(2):129–131.

Categories

All Categories